Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4997200 | 0.95 | ALDH1A1 (0.62) | ALDH1A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL21102180 | 0.94 | ALDH1A1 (0.60) | ALDH1A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4264556 | 0.94 | ALDH1A1 (0.60) | ALDH1A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4405679 | 0.94 | ALDH1A1 (0.60) | ALDH1A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL22714458 | 0.90 | ALDH1A1 (0.53) | ALDH1A1APEX1SMN1; SMN2FFAR1CYP1A2 | |
| SCHEMBL21102245 | 0.83 | ALDH1A1 (0.46) | ALDH1A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1932191 | 0.82 | ALDH1A1 (1.00) | ALDH1A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6191672 | 0.82 | ALDH1A1 (0.67) | ALDH1A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4271584 | 0.82 | ALDH1A1 (0.67) | ALDH1A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4027432 | 0.82 | ALDH1A1 (0.67) | ALDH1A1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | claimed |
| EP-4259799-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | Civi Biopharma, Inc. (US) | 2023-10-18 | — | — | EP | claimed |
| CN-116897206-A | Oral delivery of PCSK 9-targeting antisense conjugates | 四纬生物制药股份有限公司 | 2023-10-17 | — | — | CN | claimed |
| WO-2022125913-A9 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2023-06-08 | — | — | WO | claimed |
| US-20220213476-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-07-07 | — | — | US | claimed |
| WO-2022125913-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| EP-2046736-B1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2019-06-12 | — | — | EP | claimed |
| EP-2046736-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2009-04-15 | — | — | EP | claimed |
| US-7408017-B2 | Polyhydroxyalkanoate containing unit with phenylsulfanyl structure in the side chain, process for its production, charge control agent, toner binder and toner which contain novel polyhydroxyalkanoate, and image forming method and image-forming apparatus which make use of the toner | CANON KABUSHIKI KAISHA (JP) | 2008-08-05 | — | — | US | claimed |
| WO-2008014430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-01-31 | — | — | WO | claimed |
| US-7045321-B2 | POLYHYDROXYALKANOATE CONTAINING UNIT WITH PHENYLSULFANYL STRUCTURE IN THE SIDE CHAIN, PROCESS FOR ITS PRODUCTION, CHARGE CONTROL AGENT, TONER BINDER AND TONER WHICH CONTAIN NOVEL POLYHYDROXYALKANOATE, AND IMAGE-FORMING METHOD AND IMAGE-FORMING APPARATUS WHICH MAKE USE OF THE TONER | CANON KABUSHIKI KAISHA (JP) | 2006-05-16 | — | — | US | claimed |
| US-20050250191-A1 | Novel polyhydroxyalkanoate containing unit with phenylsulfanyl structure in the side chain, process for its production, charge control agent, toner binder and toner which contain novel polyhydroxyalkanoate, and image forming method and image-forming apparatus which make use of the toner | CANON KABUSHIKI KAISHA (JP) | 2005-11-10 | — | — | US | claimed |
| US-20030013841-A1 | Novel polyhydroxyalkanoate containing unit with phenylsulfanyl structure in the side chain, process for its production, charge control agent, toner binder and toner which contain novel polyhydroxyalkanoate, and image-forming method and image-forming apparatus which make use of the toner | CANON KABUSHIKI KAISHA (JP) | 2003-01-16 | — | — | US | claimed |
| EP-1236755-A2 | Novel polyhydroxyalkanoate containing unit phenylsulfanyl structure in the side cahin, process for its production, charge control agent, toner binder and toner which contain novel polyhydroxyalkanoate, and imageforming apparatus which make use of the toner | CANON KABUSHIKI KAISHA (JP) | 2002-09-04 | — | — | EP | claimed |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | CIVI BIOPHARMA, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2009100245-A1 | LOW DOSE HMG-COA REDUCTASE INHIBITOR WITH REDUCED SIDE EFFECTS | EMISPHERE TECHNOLOGIES INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100245-A1 | LOW DOSE HMG-COA REDUCTASE INHIBITOR WITH REDUCED SIDE EFFECTS | EMISPHERE TECHNOLOGIES INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2008014430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | PCSK9, ALPI, SLC10A2 | ALDH1A1 4731/4885HDAC3 1577/4885HDAC4 1427/4885 |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | ALDH1A1 4826/4885HDAC3 355/4885HDAC4 954/4885 |
| US-20220213476-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | ALDH1A1 4826/4885HDAC3 355/4885HDAC4 954/4885 |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | PCSK9, SCD5, PCSK7 | ALDH1A1 4826/4885HDAC3 355/4885HDAC4 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.